We would recognize a process which is not effective. However, anyone ho has ever tried to analyze results vs efficacy of the decision processes of FDA will come away urgently looking to take a hot shower.IMO.
[Still, members of the investigating congressional committees had harsh words for both the FDA and Biogen, the Times reported.
Rep. Frank Pallone (D.-N.J.), chair of the House Energy and Commerce Committee, said in a statement that the report "documents the atypical FDA review process and corporate greed that preceded FDA's controversial decision to grant accelerated approval to Aduhelm."
His committee conducted the investigation with the House Committee on Oversight and Reform, chaired by Rep. Carolyn Maloney (D.-N.Y.). In a statement, she said she hoped the report would be "a wake-up call for FDA to reform its practices and a call to action to my congressional colleagues to continue oversight of the pharmaceutical industry to ensure they don't put profits over patients."
More information
Visit the FDA for more on Aduhelm.
SOURCES: New York Times; U.S. House of Representatives Report, Dec. 2022